Novartis: Gilenya gets back on track with NICE approval
This article was originally published in Scrip
Executive Summary
Safety concerns and high price points have previously limited use of Novartis’s Gilenya (fingolimod) in the European multiple sclerosis market since its launch in January 2011. However, the decision by the UK's NICE to recommend Gilenya for active relapsing-remitting multiple sclerosis will support the product's future sales which are estimated to reach $2.2 billion across the seven major markets by 2020.